KRAS and neoplasm: This is in line with the findings of Rosenfeldt et al. who suggest that in the absence of TP53, autophagy is no longer required for KRAS-mediated tumor development in PDAC, although this study does not indicate that p53 status predicts the response to anti-autophagic therapy for a developed tumor (20).